Lentivirus Manufacturing for Advanced Therapies Market Revenue and Forecast by 2035
Published: 16 Dec 2025
Author: Precedence Research
Lentivirus Manufacturing for Advanced Therapies Market Revenue and Trends 2026 to 2035
The lentivirus manufacturing for advanced therapies market is expanding as demand rises for high-quality lentiviral vectors supporting gene therapy and CAR-T treatments. This market is experiencing unprecedented growth, driven by the rapidly expanding cell and gene therapy (CGT) pipeline.
What are the Factors That Have a Significant Contribution to the Growth of the Lentivirus manufacturing for advanced therapies market?
The increasing prevalence of chronic diseases such as cancer, rare diseases, and genetic diseases substantially increases the demand for cell and gene therapies, accelerating the growth of the lentivirus manufacturing for advanced therapies market during the forecast period. Moreover, rising outsourcing trends, growing demand for personalized medicine, a surge in the geriatric population, significant investment in R&D by pharma/biotech companies, rising FDA approvals for advanced therapies, and the need for scalable & regulatory-compliant vector production are expected to fuel the market's expansion.
Segment Insights
- By application, the gene therapy segment held the largest market share of 45.6% in 2025. The segment's growth is driven by rising demand for gene therapy to treat cancer and rare genetic diseases. Lentiviral vectors have emerged as critical tools in gene therapy for treating a variety of genetic illnesses, such as sickle cell disease, beta-thalassemia, and CALD.
- By end-user, the pharmaceutical & biotechnology companies segment accounted for the largest market share of 43.5% in the lentivirus manufacturing for advanced therapies market. Pharmaceutical and biotechnology companies are the major end users in the market, developing and commercializing gene and cell therapies to meet the ongoing demand for advanced therapies. Pharmaceutical and biotech companies are investing heavily in R&D for gene and cell therapies and cancer immunotherapy, crucial applications for lentiviral vectors.
- By scale of operation, the clinical/pilot-scale production segment held the largest share of 62.4% in the lentivirus manufacturing for advanced therapies market in 2025. The segment is primarily driven by the rising need to optimize upstream and downstream such as purification, concentration, and formulation.
Regional Insights
North America holds the dominant share in the global lentivirus manufacturing for advanced therapies market. The region is home to the prominent pharmaceutical and biotechnology companies. The rising prevalence of health conditions like cancer, infectious diseases, and genetic disorders such as beta-thalassemia, sickle cell, and CALD, spurs the demand for advanced therapies. The United States is a major contributor to the lentivirus manufacturing for advanced therapies market, owing to its strong presence of a well-developed network of research institutions, the rise of specialized CDMOs, increasing investment in R&D activities, increasing use of CAR-T therapy in treating cancers, and the integration of advanced technologies like artificial intelligence (AI) and machine learning. Moreover, the increasing number of regulatory approvals from the U.S. Food and Drug Administration (FDA) for lentiviral vector (LV)-based therapies is is propelling the market’s growth in the region.
On the other hand, the Asia Pacific region is anticipated to grow at the fastest rate in the market during the forecast period. The region's fastest growth is attributed to the presence of major pharmaceutical companies, the increasing trend of outsourcing, significant investment in R&D, a surge in the aging population, the growing clinical application of lentiviral vectors (LVs) in treating life-threatening diseases, and rapid technological improvements in manufacturing processes. Additionally, the growing demand for effective, targeted therapies for chronic and genetic diseases is expected to drive the market’s expansion in the region.
Lentivirus Manufacturing for Advanced Therapies Market Coverage
| Report Attribute | Key Statistics |
| Quantitative Units | Revenue in USD million/billion, Volume in units |
| Largest Market | North America |
| Base Year | 2025 |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa |
Recent Developments
- In June 2025, Cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) Porton Advanced Solutions announced the signing of a Memorandum of Understanding (MoU) with EVA Pharma, an Egypt-based company dedicated to bringing healthcare innovation to the Middle East and Africa. The partnership aims to establish and strengthen chimeric antigen receptor (CAR) T-cell therapy development and manufacturing capabilities, using EVA Pharma's facilities.(Source: https://www.bioprocessintl.com)
Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/7198
You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344